The role of 20-HETE in cardiovascular diseases and its risk factors

Prostaglandins and Other Lipid Mediators

Volumn 125, Issue , 2016, Pages 108-117

  Waldman, Maayan ^a   Peterson, Stephen J ^b   Arad, Michael ^a   Hochhauser, Edith ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

20 HETE; Cardiovascular disease (CVD); Diabetes; Obesity

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ANDROGEN; AUTACOID; HYDROXYICOSATETRAENOIC ACID; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID;

BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SMOOTH MUSCLE CONTRACTILITY; VASCULITIS; VASOCONSTRICTION; ANIMAL; BIOSYNTHESIS; CORONARY BLOOD VESSEL; DRUG EFFECTS; FIBROSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; CARDIOVASCULAR DISEASES; CORONARY VESSELS; FIBROSIS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; RISK FACTORS;

EID: 84991826925     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2016.05.007     Document Type: Review

References (181)

1. [1] Fitzpatrick, F.A., Murphy, R.C., Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of epoxygenase-derived eicosanoids. Pharmacol. Rev. 40:4 (1988), 229–241.
2. [2] Wu, C.C., Schwartzman, M.L., The role of 20-HETE in androgen-mediated hypertension. Prostaglandins Other Lipid Mediat. 96:1–4 (2011), 45–53.
3. [3] Wu, C.C., et al. 20-HETE and blood pressure regulation: clinical implications. Cardiol. Rev. 22:1 (2014), 1–12.
4. [4] Li, X., et al. 20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616. PLoS One, 9(4), 2014, e95841.
5. [5] Sacerdoti, D., et al. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243:4889 (1989), 388–390.
6. [6] Hoopes, S.L., et al. Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 120 (2015), 9–16.
7. [7] Capdevila, J.H., Wang, W., Falck, J.R., Arachidonic acid monooxygenase: genetic and biochemical approaches to physiological/pathophysiological relevance. Prostaglandins Other Lipid Mediat. 120 (2015), 40–49.
8. [8] Imig, J.D., et al. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am. J. Physiol. 270:1 Pt 2 (1996), R217–R227.
9. [9] Ito, O., et al. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am. J. Physiol. 274:2 Pt 2 (1998), F395–F404.
10. [10] Ito, O., Roman, R.J., Regulation of P-450 4A activity in the glomerulus of the rat. Am. J. Physiol. 276:6 Pt 2 (1999), R1749–R1757.
11. [11] Omata, K., Abraham, N.G., Schwartzman, M.L., Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. Am. J. Physiol. 262:4 Pt 2 (1992), F591–F599.
12. [12] Carroll, M.A., et al. Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. J. Biol. Chem. 266:19 (1991), 12306–12312.
13. [13] Escalante, B., et al. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science 251:4995 (1991), 799–802.
14. [14] Ito, O., Roman, R.J., Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension 33:1 Pt 2 (1999), 419–423.
15. [15] Carroll, M.A., et al. Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med. Sci. Monit. 7:4 (2001), 567–572.
16. [16] Croft, K.D., et al. Angiotensin II releases 20-HETE from rat renal microvessels. Am. J. Physiol. Renal Physiol. 279:3 (2000), F544–F551.
17. [17] Sun, C.W., et al. Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ. Res. 83:11 (1998), 1069–1079.
18. [18] Kalsotra, A., Strobel, H.W., Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol. Ther. 112:3 (2006), 589–611.
19. [19] Hardwick, J.P., Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol. 75:12 (2008), 2263–2275.
20. [20] Lasker, J.M., et al. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem. 275:6 (2000), 4118–4126.
21. [21] Gainer, J.V., et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111:1 (2005), 63–69.
22. [22] Muller, D.N., et al. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem. J. 403:1 (2007), 109–118.
23. [23] Holla, V.R., et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc. Natl. Acad. Sci. U. S. A. 98:9 (2001), 5211–5216.
24. [24] Xu, F., et al. Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J. Pharmacol. Exp. Ther. 308:3 (2004), 887–895.
25. [25] Stec, D.E., et al. Distribution of cytochrome P-450 4A and 4F isoforms along the nephron in mice. Am. J. Physiol. Renal Physiol. 284:1 (2003), F95–F102.
26. [26] Parmentier, J.H., et al. Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells. Life Sci. 77:9 (2005), 1015–1029.
27. [27] Ito, O., et al. Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol. Cell. Biochem. 284:1–2 (2006), 141–148.
28. [28] Williams, J.M., et al. 20-Hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 56:4 (2010), 336–344.
29. [29] Nelson, D.R., et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1 (2004), 1–18.
30. [30] Bellamine, A., et al. Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch. Biochem. Biophys. 409:1 (2003), 221–227.
31. [31] Marji, J.S., Wang, M.H., Laniado-Schwartzman, M., Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries. Am. J. Physiol. Renal Physiol. 283:1 (2002), F60–F67.
32. [32] Kim, D.H., et al. Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes. J. Lipid Res. 54:3 (2013), 786–793.
33. [33] Peterson, L.R., To lose weight or not to lose weight, that is the big question–in obesity-related heart failure. Diabetes 64:5 (2015), 1509–1510.
34. [34] Schwartzman, M.L., et al. Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J. Biol. Chem. 264:20 (1989), 11658–11662.
35. [35] Kaduce, T.L., et al. 20-Hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. J. Biol. Chem. 279:4 (2004), 2648–2656.
36. [36] Fang, X., et al. 20-Carboxy-arachidonic acid is a dual activator of peroxisome proliferator-activated receptors alpha and gamma. Prostaglandins Other Lipid Mediat. 82:1–4 (2007), 175–184.
37. [37] Carroll, M.A., et al. Cytochrome P450-derived renal HETEs: storage and release. Kidney Int. 51:6 (1997), 1696–1702.
38. [38] Oyekan, A., Balazy, M., McGiff, J.C., Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II. Am. J. Physiol. 273:1 Pt 2 (1997), R293–R300.
39. [39] Carroll, M.A., et al. Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am. J. Physiol. 271:4 Pt 2 (1996), R863–R869.
40. [40] Oyekan, A.O., McGiff, J.C., Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am. J. Physiol. 274:1 Pt 2 (1998), R52–R61.
41. [41] Imig, J.D., Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat. 104–105 (2013), 2–7.
42. [42] Alonso-Galicia, M., et al. 20-HETE agonists and antagonists in the renal circulation. Am. J. Physiol. 277:5 Pt 2 (1999), F790–F796.
43. [43] Hercule, H.C., Oyekan, A.O., Cytochrome P450 omega/omega-1 hydroxylase-derived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J. Pharmacol. Exp. Ther. 292:3 (2000), 1153–1160.
44. [44] Lee, S.J., et al. Cytochrome P-450 metabolites in endothelin-stimulated cardiac hormone secretion. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286:5 (2004), R888–R893.
45. [45] Cambj-Sapunar, L., et al. Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke 34:5 (2003), 1269–1275.
46. [46] Lin, F., et al. 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am. J. Physiol. 269:6 Pt 2 (1995), F806–F816.
47. [47] Singh, H., et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50:1 (2007), 123–129.
48. [48] Nakagawa, K., et al. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:4 (2003), R1055–R1062.
49. [49] Singh, H., Schwartzman, M.L., Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol. Rep. 60:1 (2008), 29–37.
50. [50] Coceani, F., et al. Inhibition of the contraction of the ductus arteriosus to oxygen by 1-aminobenzotriazole, a mechanism-based inactivator of cytochrome P450. Br. J. Pharmacol. 117:7 (1996), 1586–1592.
51. [51] Alonso-Galicia, M., et al. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29:1 Pt 2 (1997), 320–325.
52. [52] Alonso-Galicia, M., et al. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke 30:12 (1999), 2727–2734 (discussion 2734).
53. [53] Lopez, B., et al. Role of guanylyl cyclase and cytochrome P-450 on renal response to nitric oxide. Am. J. Physiol. Renal Physiol. 281:3 (2001), F420–F427.
54. [54] Oyekan, A.O., McGiff, J.C., Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome p450-derived arachidonate metabolites. Br. J. Pharmacol. 125:5 (1998), 1065–1073.
55. [55] Botros, F.T., Laniado-Schwartzman, M., Abraham, N.G., Regulation of cyclooxygenase- and cytochrome p450-derived eicosanoids by heme oxygenase in the rat kidney. Hypertension 39:2 Pt 2 (2002), 639–644.
56. [56] Hoagland, K.M., Maier, K.G., Roman, R.J., Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl salt-sensitive rats. Hypertension 41:3 Pt 2 (2003), 697–702.
57. [57] Minuz, P., et al. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 51:5 (2008), 1379–1385.
58. [58] Heng, Y.M., et al. A novel murine P-450 gene, Cyp4a14, is part of a cluster of Cyp4a and Cyp4b, but not of CYP4F, genes in mouse and humans. Biochem. J. 325:Pt 3 (1997), 741–749.
59. [59] Nakagawa, K., et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J. Clin. Invest. 116:6 (2006), 1696–1702.
60. [60] Gangadhariah, M.H., et al. Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. J. Am. Soc. Nephrol. 26:3 (2015), 597–610.
61. [61] Roman, R.J., et al. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 21:6 Pt 2 (1993), 985–988.
62. [62] Wilson, T.W., Alonso-Galicia, M., Roman, R.J., Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31:1 Pt 2 (1998), 225–231.
63. [63] Laffer, C.L., et al. 20-HETE and circulating insulin in essential hypertension with obesity. Hypertension 43:2 (2004), 388–392.
64. [64] Vera, T., et al. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension 45:4 (2005), 730–735.
65. [65] Zhou, Y., et al. Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats. J. Pharmacol. Exp. Ther. 317:1 (2006), 11–18.
66. [66] Zhou, Y., et al. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am. J. Hypertens. 18:4 Pt 1 (2005), 530–537.
67. [67] Wang, J., et al. Effects of high-salt diet on CYP450-4A omega-hydroxylase expression and active tone in mesenteric resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 288:4 (2005), H1557–H1565.
68. [68] Omata, K., et al. Effect of aging on renal cytochrome P450-dependent arachidonic acid metabolism in Dahl rats. J. Lipid Mediat. 6:1–3 (1993), 369–373.
69. [69] Wu, J.H., et al. Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and human studies. Hypertension 54:5 (2009), 1151–1158.
70. [70] Ward, N.C., et al. The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J. Hypertens. 32:7 (2014), 1495–1502 (discussion 1502).
71. [71] Le, T.H., Coffman, T.M., Targeting genes in the renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 17:1 (2008), 57–63.
72. [72] Cvetkovic, B., Sigmund, C.D., Understanding hypertension through genetic manipulation in mice. Kidney Int. 57:3 (2000), 863–874.
73. [73] Urbich, C., Dimmeler, S., Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95:4 (2004), 343–353.
74. [74] Giannotti, G., Landmesser, U., Endothelial dysfunction as an early sign of atherosclerosis. Herz 32:7 (2007), 568–572.
75. [75] Gehling, U.M., et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:10 (2000), 3106–3112.
76. [76] Alonso-Galicia, M., et al. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283:1 (2002), R60–R68.
77. [77] Eid, S., et al. Involvement of renal cytochromes P450 and arachidonic acid metabolites in diabetic nephropathy. J. Biol. Regul. Homeost. Agents 27:3 (2013), 693–703.
78. [78] Nie, D., et al. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 95:7 (2000), 2304–2311.
79. [79] Peichev, M., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:3 (2000), 952–958.
80. [80] Theken, K.N., et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 222:2 (2012), 530–536.
81. [81] Chabova, V.C., et al. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul. Pharmacol. 47:2–3 (2007), 145–159.
82. [82] Mollnau, H., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90:4 (2002), E58–E65.
83. [83] Huang, X.C., Richards, E.M., Sumners, C., Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. J. Biol. Chem. 271:26 (1996), 15635–15641.
84. [84] Guo, A.M., et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J. Pharmacol. Exp. Ther. 321:1 (2007), 18–27.
85. [85] Guo, A.M., et al. 20-HETE can act as a nonhypoxic regulator of HIF-1alpha in human microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 297:2 (2009), H602–H613.
86. [86] Ishizaka, N., et al. Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation 96:6 (1997), 1923–1929.
87. [87] Landmesser, U., Drexler, H., Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J. Hypertens. Suppl. 24:1 (2006), S39–S43.
88. [88] Morgan-Boyd, R., et al. Effects of bradykinin and angiotensin II on intracellular Ca2+ dynamics in endothelial cells. Am. J. Physiol. 253:4 Pt 1 (1987), C588–C598.
89. [89] Wolf, G., Neilson, E.G., Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int. Suppl. 39 (1993), S100–S107.
90. [90] Ishizuka, T., et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J. Pharmacol. Exp. Ther. 324:1 (2008), 103–110.
91. [91] Cheng, J., et al. Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 32:8 (2012), 1917–1924.
92. [92] Dunn, K.M., et al. Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 295:6 (2008), H2455–H2465.
93. [93] Garcia, V., et al. Androgen-induced hypertension in angiotensinogen deficient mice: role of 20-HETE and EETS. Prostaglandins Other Lipid Mediat. 116–117 (2015), 124–130.
94. [94] Imig, J.D., 20-Hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension. Hypertension 56:5 (2010), 822–823.
95. [95] Garcia, V., et al. Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309:1 (2015), R71–R78.
96. [96] Harder, D.R., et al. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am. J. Physiol. 266:5 Pt 2 (1994), H2098–H2107.
97. [97] Zhu, D., et al. CYP4A mRNA, protein, and product in rat lungs: novel localization in vascular endothelium. J. Appl. Physiol. (1985) 93:1 (2002), 330–337.
98. [98] Escalante, B., et al. Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J. Pharmacol. Exp. Ther. 248:1 (1989), 229–232.
99. [99] Ma, Y.H., et al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ. Res. 72:1 (1993), 126–136.
100. [100] Inoue, R., et al. Synergistic activation of vascular TRPC6 channel by receptor and mechanical stimulation via phospholipase C/diacylglycerol and phospholipase A2/omega-hydroxylase/20-HETE pathways. Circ. Res. 104:12 (2009), 1399–1409.
101. [101] Randriamboavonjy, V., Busse, R., Fleming, I., 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 41:3 Pt 2 (2003), 801–806.
102. [102] Kaide, J., et al. Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries. Am. J. Physiol. Renal Physiol. 284:1 (2003), F51–F56.
103. [103] Wang, M.H., et al. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280:1 (2001), R255–R261.
104. [104] Zhang, F., et al. Transfection of CYP4A1 cDNA decreases diameter and increases responsiveness of gracilis muscle arterioles to constrictor stimuli. Am. J. Physiol. Heart Circ. Physiol. 287:3 (2004), H1089–H1095.
105. [105] Roman, R.J., P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82:1 (2002), 131–185.
106. [106] Orozco, L.D., et al. 20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries. J. Pharmacol. Exp. Ther. 346:1 (2013), 67–74.
107. [107] Frisbee, J.C., et al. Impairment of flow-induced dilation of skeletal muscle arterioles with elevated oxygen in normotensive and hypertensive rats. Microvasc. Res. 60:1 (2000), 37–48.
108. [108] Yanes, L.L., et al. Postmenopausal hypertension: role of 20-HETE. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300:6 (2011), R1543–R1548.
109. [109] Lima, R., et al. Roles played by 20-HETE, angiotensin II and endothelin in mediating the hypertension in aging female spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304:3 (2013), R248–R251.
110. [110] Schulz, E., et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid. Redox Signal. 10:6 (2008), 1115–1126.
111. [111] Ignarro, L.J., Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 30 (1990), 535–560.
112. [112] Mitchell, J.A., et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp. Physiol. 93:1 (2008), 141–147.
113. [113] Harrison, D.G., Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 100:9 (1997), 2153–2157.
114. [114] Cai, H., Harrison, D.G., Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:10 (2000), 840–844.
115. [115] Frisbee, J.C., Falck, J.R., Lombard, J.H., Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am. J. Physiol. Heart Circ. Physiol. 278:5 (2000), H1517–H1526.
116. [116] Wang, J.S., et al. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ. Res. 98:7 (2006), 962–969.
117. [117] Sodhi, K., et al. CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent. Hypertension 56:5 (2010), 871–878.
118. [118] Inoue, K., et al. Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am. J. Physiol. Renal Physiol. 297:4 (2009), F875–F884.
119. [119] Ward, N.C., et al. Chronic activation of AMP-activated protein kinase prevents 20-hydroxyeicosatetraenoic acid-induced endothelial dysfunction. Clin. Exp. Pharmacol. Physiol. 38:5 (2011), 328–333.
120. [120] Ward, N.C., et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110:4 (2004), 438–443.
121. [121] Izzard, A.S., et al. Small artery structure and hypertension: adaptive changes and target organ damage. J. Hypertens. 23:2 (2005), 247–250.
122. [122] Schiffrin, E.L., Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am. J. Hypertens. 17:12 Pt 1 (2004), 1192–1200.
123. [123] Marchesi, C., Paradis, P., Schiffrin, E.L., Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 29:7 (2008), 367–374.
124. [124] Verma, S., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:17 (2004), 2058–2067.
125. [125] Seeger, F.H., et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 111:9 (2005), 1184–1191.
126. [126] Szmitko, P.E., et al. New markers of inflammation and endothelial cell activation: part I. Circulation 108:16 (2003), 1917–1923.
127. [127] Szmitko, P.E., et al. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation 108:17 (2003), 2041–2048.
128. [128] Alom-Ruiz, S.P., Anilkumar, N., Shah, A.M., Reactive oxygen species and endothelial activation. Antioxid. Redox Signal. 10:6 (2008), 1089–1100.
129. [129] Schober, A., Zernecke, A., Chemokines in vascular remodeling. Thromb. Haemost. 97:5 (2007), 730–737.
130. [130] Zhang, C., The role of inflammatory cytokines in endothelial dysfunction. Basic Res. Cardiol. 103:5 (2008), 398–406.
131. [131] Guzik, T.J., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204:10 (2007), 2449–2460.
132. [132] Liao, T.D., et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 52:2 (2008), 256–263.
133. [133] Csiszar, A., et al. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J. Appl. Physiol. (1985) 105:4 (2008), 1333–1341.
134. [134] Baeuerle, P.A., IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95:6 (1998), 729–731.
135. [135] Donato, A.J., et al. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ. Res. 100:11 (2007), 1659–1666.
136. [136] Ungvari, Z., et al. Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am. J. Physiol. Heart Circ. Physiol. 293:1 (2007), H37–H47.
137. [137] Sung, B., et al. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. Exp. Gerontol. 41:6 (2006), 590–599.
138. [138] Chung, H.Y., et al. The molecular inflammatory process in aging. Antioxid. Redox Signal. 8:3–4 (2006), 572–581.
139. [139] de Winther, M.P., et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25:5 (2005), 904–914.
140. [140] Savoia, C., Schiffrin, E.L., Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin. Sci. (Lond.) 112:7 (2007), 375–384.
141. [141] Theuer, J., et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc. Disord., 2, 2002, 3.
142. [142] Henke, N., et al. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res. 101:3 (2007), 268–276.
143. [143] Garcia, V., Shkolnik, B., Milhau, L., Falck, J.R., Schwartzman, M.L., 20-HETE activates the transcription of angiotensin-converting enzyme via nuclear factor-κB translocation and promoter binding. J. Pharmacol. Exp. Ther. 356:Mar (3) (2016), 525–533.
144. [144] Hoff, U., et al. Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int. 79:1 (2011), 57–65.
145. [145] Liu, Y., et al. The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res. 1544 (2014), 45–53.
146. [146] Miyata, N., Roman, R.J., Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res. 41:4 (2005), 175–193.
147. [147] Toth, P., et al. Treatment with the cytochrome P450 omega-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats. Br. J. Pharmacol. 168:8 (2013), 1878–1888.
148. [148] Issan, Y., et al. Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemia. Prostaglandins Other Lipid Mediat. 100–101 (2013), 15–21.
149. [149] Yousif, M., Benter, I., Roman, R., Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton. Autacoid Pharmacol. 29:1–2 (2009), 33–41.
150. [150] Theken, K.N., et al. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am. J. Physiol. Endocrinol. Metab. 302:5 (2011), E500–E509.
151. [151] Issan, Y., et al. Endothelial progenitor cell function inversely correlates with long-term glucose control in diabetic patients: association with the attenuation of the heme oxygenase-adiponectin axis. Can. J. Cardiol. 28:6 (2012), 728–736.
152. [152] Fadini, G.P., et al. Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells 24:7 (2006), 1806–1813.
153. [153] Fleming, I., The cytochrome P450 pathway in angiogenesis and endothelial cell biology. Cancer Metastasis Rev. 30:3–4 (2011), 541–555.
154. [154] Guo, A.M., et al. The cytochrome P450 4A/F-20-hydroxyeicosatetraenoic acid system: a regulator of endothelial precursor cells derived from human umbilical cord blood. J. Pharmacol. Exp. Ther. 338:2 (2011), 421–429.
155. [155] Steiner, D.R., Gonzalez, N.C., Wood, J.G., Leukotriene B(4) promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J. Appl. Physiol. (1985) 91:3 (2001), 1160–1167.
156. [156] Walenta, K.L., et al. Differential chemokine receptor expression regulates functional specialization of endothelial progenitor cell subpopulations. Basic Res. Cardiol. 106:2 (2010), 299–305.
157. [157] Finkensieper, A., et al. The 5-lipoxygenase pathway regulates vasculogenesis in differentiating mouse embryonic stem cells. Cardiovasc. Res. 86:1 (2010), 37–44.
158. [158] Gubitosi-Klug, R.A., et al. 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes 57:5 (2008), 1387–1393.
159. [159] Ward, N.C., et al. 20-Hydroxyeicosatetraenoic acid is not associated with circulating insulin in lean to overweight humans. Diabetes Res. Clin. Pract. 74:2 (2006), 197–200.
160. [160] Tsai, I.J., et al. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. Free Radic. Biol. Med. 46:2 (2009), 263–270.
161. [161] Ward, N.C., et al. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic. Biol. Med. 38:8 (2005), 1032–1036.
162. [162] Hinglais, N., et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab. Invest. 70:2 (1994), 286–294.
163. [163] Ratcliffe, N.R., et al. Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis. J. Autoimmun. 15:3 (2000), 359–367.
164. [164] Kanzaki, Y., et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn. Circ. J. 65:9 (2001), 797–802.
165. [165] Hayashidani, S., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108:17 (2003), 2134–2140.
166. [166] Nithipatikom, K., et al. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal. Biochem. 292:1 (2001), 115–124.
167. [167] Nithipatikom, K., et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ. Res. 95:8 (2004), e65–e71.
168. [168] Gross, E.R., et al. Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J. Mol. Cell. Cardiol. 37:6 (2004), 1245–1249.
169. [169] Gross, G.J., et al. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc. Res. 68:1 (2005), 18–25.
170. [170] Levick, S.P., et al. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J. Immunol. 178:2 (2007), 641–646.
171. [171] Kroetz, D.L., Xu, F., Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu. Rev. Pharmacol. Toxicol. 45 (2005), 413–438.
172. [172] Su, P., Kaushal, K.M., Kroetz, D.L., Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am. J. Physiol. 275:2 Pt 2 (1998), R426–R438.
173. [173] Muerhoff, A.S., et al. Prostaglandin and fatty acid omega- and (omega-1)-oxidation in rabbit lung. Acetylenic fatty acid mechanism-based inactivators as specific inhibitors. J. Biol. Chem. 264:2 (1989), 749–756.
174. [174] Wang, M.H., et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J. Pharmacol. Exp. Ther. 284:3 (1998), 966–973.
175. [175] Hacein-Bey, L., et al. Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am. J. Neuroradiol. 27:6 (2006), 1350–1354.
176. [176] Miyata, N., et al. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br. J. Pharmacol. 133:3 (2001), 325–329.
177. [177] Seki, T., et al. Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N′-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol. Pharm. Bull. 28:9 (2005), 1651–1654.
178. [178] Yu, M., et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur. J. Pharmacol. 486:3 (2004), 297–306.
179. [179] Tunctan, B., et al. A 20-hydroxyeicosatetraenoic acid agonist: N-20-hydroxyeicosa-5(Z),14(Z)-dienoylglycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock 30:3 (2008), 329–335.
180. [180] Regner, K.R., et al. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int. 75:5 (2009), 511–517.
181. [181] Peterson, S.J., Vanella, L., Gotlinger, K., Jiang, H., Singh, S.P., Sodhi, K., Maher, E., O'Hanlon, K., Shapiro, J.I., Abraham, N.G., Oxidized HDL is a potent inducer of adipogenesis and causes activation of the Ang-II and 20-HETE systems in human obese females. Prostaglandins Other Lipid Mediat. 123 (2016), 68–77.